Under construction – not a live service
Sign in
Not yet taking people in EgyptNo phase

Modified Atkins Diet in Children With Epilepsy That Medicines Do Not Control

Looks at how a modified Atkins diet affects children with drug resistant epilepsy.

Plain-language title generated from the registry record
Registry title: Outcomes of Drug Resistant Epileptic Pediatric Patient by Modified Atkins Diet

Key facts

Where
Sohag, EgyptSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 18 years old?

Source: NCT07275125, who can take part

Where in Egypt

  • Sohag faculty of medicineSohag, EgyptNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sohag University
Trial code
NCT07275125
Record updated
10 December 2025
Original description
To assess clinical outcomes in drug resistant epileptic pediatric patient by modified atkin diet with focusing on following points:Read full original descriptionShow less

Outcomes of Drug Resistant Epileptic Pediatric Patient by Modified Atkins Diet

To assess clinical outcomes in drug resistant epileptic pediatric patient by modified atkin diet with focusing on following points:

1. Control of seizures(frequency , duration and numbers of hospital admissions) . 2. Quality of life by pediatric quality of life inventory v4. 3. Cognitive function by stanford binet intelligence scale 5th edition. 4. Growth parameters ( weight, height will be combined to report BMI in kg/m\^2).

Inclusion: Children aged 1-18 years; Diagnosed with drug-resistant epilepsy according to ILAE definition.[2]; On KD for at least 6 months.

Exclusion: Non-compliance with KD ; Patients on alternative dietary therapies (e.g., low glycemic diet); - Patients with contraindicated metabolic/genetic conditions.

ClinicalTrials.gov NCT07275125